In La Jolla, California, on April 27, 2026, MediciNova, Inc. revealed that a study conducted by researchers at the Spanish National Cancer Research Centre (CNIO) pinpointed a significant discovery in brain metastasis. The researchers identified that macrophage migration inhibitory factor (MIF) plays a crucial role in reprogramming CD74-positive microglia and macrophages. This vulnerability was detailed in a recent publication in the reputable journal "Cancer Research" from March 2026. The study showcased the effectiveness of ibudilast, a brain-penetrant small molecule, in modulating this pathway. MediciNova, Inc. is a biopharmaceutical company listed on the NASDAQ Global Market under the ticker symbol MNOV and the Tokyo Stock Exchange under Code Number 4875.